Galedra
Sign in Sign up

Claims

As of snapshot 27745 under ledger-default@0.3.0.

ClaimTypeAssessmentScoreReview checksReferences
In the phase II randomized RIO trial of 68 adult men living with HIV who interrupted ART, long-acting 3BNC117-LS and 10-1074-LS delayed viral rebound: median ART restart was 45.4 weeks with antibodies versus 4.6 weeks with placebo, and intact proviruses declined in the antibody arm. QUANTITATIVE Supported 0.9468 1 of 4 104